Abstract:
The present application provides materials and methods for treating hemoglobinopathies. More specifically, the application provides methods for producing progenitor cells that are genetically modified via genome editing to increase the production of fetal hemoglobin (HbF), as well as modified progenitor cells (including, for example, CD34+ human hematopoietic stem cells) producing increased levels of HbF, and methods of using such cells for treating hemoglobinopathies such as sickle cell anemia and β-thalassemia.
Abstract:
Methods and systems for searching genomes for potential CRISPR off-target sites are provided. In preferred embodiments, the methods include identifying possible on- and off-target cleavage sites and/or ranking the potential off-target sites based on the number and location of mismatches, insertions, and/or deletions in the gRNA guide sequence relative to the genomic DNA sequence at a putative target site in the genome. These methods allow for the selection of better target sites and/or experimental confirmation of off-target sites and are an improvement over partial search mechanisms that fail to locate every possible target site.
Abstract:
Methods and systems for searching genomes for potential nucleotide-guided nuclease off-target sites are provided. Also provided are methods of searching genomes for potential off-target deadCas9 binding sites. In some embodiments, the methods include ranking the potential off-target sites based on the number and location of mismatches, insertions, and/or deletions in the DNA, RNA, or DNA/RNA guide sequence relative to the genomic DNA sequence at a putative target site in the genome, allowing the selection of better target sites and/or experimental confirmation of off-target sites.
Abstract:
Methods and systems for searching genomes for potential CRISPR off-target sites are provided. In preferred embodiments, the methods include identifying possible on- and off-target cleavage sites and/or ranking the potential off-target sites based on the number and location of mismatches, insertions, and/or deletions in the gRNA guide sequence relative to the genomic DNA sequence at a putative target site in the genome. These methods allow for the selection of better target sites and/or experimental confirmation of off-target sites and are an improvement over partial search mechanisms that fail to locate every possible target site.
Abstract:
Methods and systems for searching genomes for potential nucleotide-guided nuclease off-target sites are provided. Also provided are methods of searching genomes for potential off-target deadCas9 binding sites. In some embodiments, the methods include ranking the potential off-target sites based on the number and location of mismatches, insertions, and/or deletions in the DNA, RNA, or DNA/RNA guide sequence relative to the genomic DNA sequence at a putative target site in the genome, allowing the selection of better target sites and/or experimental confirmation of off-target sites.
Abstract:
Methods and systems for searching genomes for potential CRISPR off-target sites are provided. In preferred embodiments, the methods include identifying possible on- and off-target cleavage sites and /or ranking the potential off-target sites based on the number and location of mismatches, insertions, and/or deletions in the gRNA guide sequence relative to the genomic DNA sequence at a putative target site in the genome. These methods allow for the selection of better target sites and/or experimental confirmation of off-target sites and are an improvement over partial search mechanisms that fail to locate every possible target site.